Pharmacological background of EGFR targeting.

@article{Castillo2004PharmacologicalBO,
  title={Pharmacological background of EGFR targeting.},
  author={Lesley Castillo and Marie-Christine Etienne-Grimaldi and Jean Louis Fischel and Patricia Formento and Nicolas Magn{\'e} and G{\'e}rard Milano},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2004},
  volume={15 7},
  pages={1007-12}
}
Epidermal growth factor receptor (EGFR) signaling pathways play a key role in the regulation of cell proliferation, survival and differentiation. As a consequence, EGFR is one of the best studied ligand-receptor system and specific EGFR inhibition approaches are currently among the most promising and the most advanced in the clinical setting. Monoclonal antibodies (mAbs) and specific tyrosine kinase inhibitors (TKIs) have been developed, among which C225 (Cetuximab) and ZD1839 (Iressa… CONTINUE READING